Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Indirect-Acting Cholinergic Agonists: Pharmacological Actions01:30

Indirect-Acting Cholinergic Agonists: Pharmacological Actions

1.8K
Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
1.8K
Cholinergic Antagonists: Pharmacological Actions01:28

Cholinergic Antagonists: Pharmacological Actions

2.0K
Antimuscarinic drugs block muscarinic receptors in multiple systems, including the gut, eye, smooth muscles, respiratory tract, cardiovascular, and central nervous systems. They produce similar effects with varying selectivity depending on the specific agent and tissue. Here are the key pharmacological actions of antimuscarinics:
Gastrointestinal Effects: Antimuscarinics reduce gut contractions, increase gastric emptying, and slow intestinal transit. They partly inhibit gastric acid secretion...
2.0K
Cholinergic Antagonists: Pharmacokinetics01:24

Cholinergic Antagonists: Pharmacokinetics

1.1K
Cholinergic antagonists—such as antimuscarinics—are available in oral, topical, ocular, parenteral, and inhalational formulations. Most antimuscarinics are oral formulations,  while scopolamine is available as a topical patch, and ipratropium and tiotropium are available as inhalation aerosols or powders. Atropine, tropicamide, and cyclopentolate are topically instilled in the eye. Most antimuscarinics are lipid-soluble and readily absorbed from the gastrointestinal tract and...
1.1K
Cholinergic Antagonists: Therapeutic Uses01:26

Cholinergic Antagonists: Therapeutic Uses

1.7K
Antimuscarinic drugs have various therapeutic applications by inhibiting parasympathetic stimulation in different systems. Here are the key therapeutic uses of antimuscarinics:    
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal...
1.7K
Cholinergic Antagonists: Chemistry and Structure-Activity Relationship01:29

Cholinergic Antagonists: Chemistry and Structure-Activity Relationship

3.0K
Cholinergic antagonists bind to cholinergic receptors and limit the effects of acetylcholine and other cholinergic agonists. Based on the specific cholinergic receptor affinity, these antagonists are classified as muscarinic or nicotinic. Anticholinergics interrupt parasympathetic innervations while sympathetic innervations remain uninterrupted. Muscarinic antagonists are also called 'muscarinic antagonists', 'antimuscarinics', or 'parasympatholytics'. Nicotinic...
3.0K
Agonism and Antagonism: Quantification01:14

Agonism and Antagonism: Quantification

1.3K
When drugs are administered, they can elicit either an agonist or antagonist effect on the body. Agonism occurs when a drug activates a specific receptor, triggering a biological response. On the other hand, antagonism happens when a drug binds to the same receptors but blocks their activation, thereby preventing a biological response.
To quantify these effects, researchers use a dose-response curve, which provides valuable information about the potency and efficacy of a drug. Potency refers to...
1.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Statins and brain integrity in older adults: secondary analysis of the Health ABC study.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2015
Same author

Resting heart rate and risk of incident heart failure: three prospective cohort studies and a systematic meta-analysis.

Journal of the American Heart Association·2015
Same author

The Pittsburgh Fatigability scale for older adults: development and validation.

Journal of the American Geriatrics Society·2015
Same author

Visual impairment and incident mobility limitations: the health, aging and body composition study.

Journal of the American Geriatrics Society·2014
Same author

Statin use and decline in gait speed in community-dwelling older adults.

Journal of the American Geriatrics Society·2014
Same author

Impact of visceral fat on skeletal muscle mass and vice versa in a prospective cohort study: the Korean Sarcopenic Obesity Study (KSOS).

PloS one·2014
Same journal

Caregiver Burden at the Onset of Acute Hospital-At-Home.

Journal of the American Geriatrics Society·2026
Same journal

Utilization Patterns Among Heterogeneous Subgroups of Homebound Older Adults: A Latent Class Analysis.

Journal of the American Geriatrics Society·2026
Same journal

Off-Label Initiation of Gabapentin and Valproic Acid Among Long-Stay Nursing Home Residents With and Without Dementia.

Journal of the American Geriatrics Society·2026
Same journal

The DOAC-FRAIL Study-Same Dose, Different Story: Prevalence of Deviant Direct Oral Anticoagulant Levels in Nursing Home Residents.

Journal of the American Geriatrics Society·2026
Same journal

Practice Environment and Job Outcomes Among Primary Care Nurse Practitioners Caring for Patients With Dementia.

Journal of the American Geriatrics Society·2026
Same journal

Anticholinergic Medication Use in Veterans Affairs Long-Term Care Residents: Clinical Patterns and Opportunities for Deprescribing.

Journal of the American Geriatrics Society·2026
See all related articles

Related Experiment Video

Updated: Mar 31, 2026

A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development
07:02

A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development

Published on: February 11, 2019

10.4K

Concordance Between Anticholinergic Burden Scales.

Jennifer G Naples1,2,3, Zachary A Marcum4, Subashan Perera1,5

  • 1Division of Geriatrics, Department of Medicine, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania.

Journal of the American Geriatrics Society
|October 21, 2015
PubMed
Summary
This summary is machine-generated.

Five anticholinergic scales showed low to moderate agreement in measuring medication use among older adults. Further research is needed to understand how these differences impact clinical outcomes like cognitive impairment.

Keywords:
agedcholinergic antagonistsdrug use

More Related Videos

Quantitative Autonomic Testing
11:40

Quantitative Autonomic Testing

Published on: July 19, 2011

59.1K

Related Experiment Videos

Last Updated: Mar 31, 2026

A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development
07:02

A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development

Published on: February 11, 2019

10.4K
Quantitative Autonomic Testing
11:40

Quantitative Autonomic Testing

Published on: July 19, 2011

59.1K

Area of Science:

  • Gerontology
  • Pharmacology
  • Clinical Pharmacy

Background:

  • Anticholinergic medications are frequently used by older adults.
  • Several scales exist to measure anticholinergic burden, but their concordance is not well-established.
  • Understanding measurement concordance is crucial for accurate clinical assessment.

Purpose of the Study:

  • To evaluate the concordance of five commonly used anticholinergic scales.
  • To compare different methods for quantifying anticholinergic medication exposure in elderly individuals.

Main Methods:

  • Cross-sectional secondary analysis of data from 3,055 community-dwelling adults aged 70-79.
  • Utilized five anticholinergic measures: Anticholinergic Cognitive Burden (ACB) Scale, Anticholinergic Drug Scale (ADS), Anticholinergic Risk Scale (ARS), Drug Burden Index anticholinergic component (DBI-ACh), and Summated Anticholinergic Medications Scale (SAMS).
  • Assessed concordance using kappa statistics and Spearman rank correlations.

Main Results:

  • Prevalence of any anticholinergic use varied significantly across scales (51% ACB to 16% SAMS).
  • Pairwise kappa statistics for use ranged from 0.33 to 0.68, indicating low to moderate agreement.
  • Weighted kappa for scales without dosage information ranged from 0.54 to 0.70.
  • Spearman correlation between DBI-ACh and SAMS was 0.50.

Conclusions:

  • There is limited concordance among the five evaluated anticholinergic scales.
  • The discrepancies highlight the need for further investigation into how these measurement differences influence predictive validity for clinical outcomes, such as cognitive impairment.